Table 3 Review of the literature on radiotherapy outcomes of pulmonary ACC
From: Stereotactic body radiotherapy for adenoid cystic carcinoma metastatic to the lung: a case report
Authors | No. of patients | Radiotherapy dose, BED2Gy | Follow-up (months) | Combination therapy | Treatment outcome | Adverse events |
|---|---|---|---|---|---|---|
Bhandari V [11] | 1 | 54 Gy/30fr., 102.6 Gy | 8 | – | No evidence of recurrence | Bronchial stricture grade 1 |
Das S [13] | 1 | 66 Gy/33 fr., 132 Gy | 38 | – | Local recurrence | NR |
Haresh KP [14] | 1 | 60 Gy/30 fr., 120 Gy | 19 | – | No evidence of recurrence | NR |
Kanematsu T [15] | 5 | 50–70 Gy (median 60 Gy), 100–140 Gy (median 120 Gy) | NR | – | Local recurrence in all five cases (5-year OS, 40%; 10-year OS, 0%) | NR |
Kim B [16] | 1 | 66 Gy/33 fr., 132 Gy | 20 | Paclitaxel, cisplatin, docetaxel, gefitinib | Dead without local recurrence | Radiation pneumonitis grade 1 |
Lee JH [17] | 12 | 60 Gy/30 fr., 120 Gy | 8–167 (median 59) | – | 5 year OS, 54%; 10-year OS, 27% | NR |
Liu J [18] | 1 | 65 Gy/35 fr. + endobronchial boost 10 Gy/1 fr., 125.4 Gy + 60 Gy | 90 | Cisplatin | Local recurrence | Esophagitis grade 3, skin reaction grade 1, and bronchial stricture grade 1 |